Cognuse Neuroscience focuses on empowering patients and healthcare professionals through innovative digital solutions designed to enhance care and improve patient outcomes. Their offerings include a Patient ICU dashboard that facilitates active participation from patients and families, interactive diagnostic content, and therapy exercises that extend therapeutic resources. The platform emphasizes guideline management, providing actionable guidelines and continuous education to healthcare providers, while also supporting real-time adherence and compliance. Features such as an Interactive Day Planner and automated discharge documentation aim to improve communication between facilities and patients, ultimately fostering patient independence and involvement from family members.

In addition to their core products, Cognuse is engaged in various research initiatives aimed at advancing healthcare technology. One notable project is the Innovative Consent Service Development (INA), which seeks to create a trusted consent handling solution for healthcare institutions. This project leverages Guardtime’s Health technology to ensure data integrity and informed consent management. Cognuse is also involved in ongoing studies, such as the CONCARE feasibility study, which aims to improve outcomes for critically ill patients by leveraging mobile technology for continuous care. Their commitment to research is further demonstrated through collaborations with academic institutions to evaluate the effectiveness of their interactive applications in cognitive rehabilitation and emotional health assessments.

Estonia

Cognuse is a digital health company that focuses on building IT solutions for healthcare professionals and patients to improve care quality, outcomes, and reduce complications by enhancing guidelines adherence.

Cognuse Neuroscience

Company Details